HRG2005
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 23, 2025
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=82 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=200 ➔ 82 | Trial completion date: Aug 2025 ➔ Feb 2025 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2025 ➔ Feb 2025; Sponsor's R&D strategy adjusted.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
January 30, 2024
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=200 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
September 13, 2023
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1